BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 2840186)

  • 1. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
    Merchant RE; Grant AJ; Merchant LH; Young HF
    Cancer; 1988 Aug; 62(4):665-71. PubMed ID: 2840186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.
    Merchant RE; Merchant LH; Cook SH; McVicar DW; Young HF
    Neurosurgery; 1988 Dec; 23(6):725-32. PubMed ID: 2851116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
    Munari L; Silvani A; Passerini CG; Radrizzani M; Parmiani G; Boiardi A
    J Neurosurg Sci; 1990; 34(3-4):283-8. PubMed ID: 1965907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.
    Blancher A; Roubinet F; Grancher AS; Tremoulet M; Bonaté A; Delisle MB; Calot JP; Pourreau C; Franks C; Ducos J
    Eur Cytokine Netw; 1993; 4(5):331-41. PubMed ID: 8117934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report.
    Naganuma H; Kimurat R; Sasaki A; Fukamachi A; Nukui H; Tasaka K
    Acta Neurochir (Wien); 1989; 99(3-4):157-60. PubMed ID: 2549767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
    Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
    Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients.
    Cascinelli N; Belli F; Marchini S; Marolda R; Prada A; Sciorelli G; Villani F; Gambacorti-Passerini C; Galazka A; Parmiani G
    Tumori; 1989 Jun; 75(3):233-44. PubMed ID: 2788945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.
    Lillehei KO; Mitchell DH; Johnson SD; McCleary EL; Kruse CA
    Neurosurgery; 1991 Jan; 28(1):16-23. PubMed ID: 1994273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.
    Boiardi A; Silvani A; Ruffini PA; Rivoltini L; Parmiani G; Broggi G; Salmaggi A
    Cancer Immunol Immunother; 1994 Sep; 39(3):193-7. PubMed ID: 7923250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
    Yoshida S; Tanaka R; Takai N; Ono K
    Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
    Yoshida S; Takai N; Ono K; Saito T; Tanaka R
    No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma.
    Dillman RO; Duma CM; Schiltz PM; DePriest C; Ellis RA; Okamoto K; Beutel LD; De Leon C; Chico S
    J Immunother; 2004; 27(5):398-404. PubMed ID: 15314549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors.
    Nakagawa K; Kamezaki T; Shibata Y; Tsunoda T; Meguro K; Nose T
    Neurol Med Chir (Tokyo); 1995 Jan; 35(1):22-7. PubMed ID: 7700478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.